Axe Compute Inc. is focused on artificial intelligence (AI) compute accessible to all through its access to the Aethir network. By delivering Aethir-provided decentralized global infrastructure, the Company will endeavor to deliver instant access to bare-metal GPUs at scale to innovators and established businesses alike. Dedicated GPU clusters delivered in 48 hours across 200+ locations. It offers Zero Virtualization Overhead, Purpose-Built for AI Workloads, Flat Rate, Zero Egress Fees, and Enterprise-Grade Support and SLAs. It provides 100% bare-metal access.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	40.99M 35.36M 32.51M 30.6M 57.5M 3.87B 57.99M 385M 150M 1.9B 154M 151M 6.57B	P/E 2024	-0.35x	P/E 2025	-0.53x
Enterprise Value	31.87M 27.49M 25.27M 23.79M 44.7M 3.01B 45.08M 300M 117M 1.48B 120M 117M 5.11B	EV / Sales 2024	4.23x	EV / Sales 2025	121x
Free-Float	87.13%	Yield 2024 *	-	Yield 2025	-

06-16	Axe Compute Inc. Secures $25.9 Million in Contracts for Long-Term Deployments of Blackwell and Grace Blackwell Compute	CI
06-10	Axe Compute Files $1 Billion Mixed Shelf	MT
05-27	Axe Compute Inc. Receives $43 Million Payment for Landmark Contract	CI
05-18	Axe Compute Inc., Q1 2026 Earnings Call, May 18, 2026
04-22	Top Midday Gainers	MT
04-22	Axe Compute Receives $260 Million Contract to Provide Nvidia B300 Chips; Shares Jump Pre-Bell	MT
04-22	Axe Compute Inc Secures $260 Million Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment	CI
04-20	Axe Compute Inc Announces Strategic Compute Reserve Dashboard Launch	CI
04-17	Axe Compute Inc - Josh Blacher to resign as CFO effective May 18, 2026 - SEC filing	RE
04-17	Axe Compute Inc. Announces Change of Chief Financial Officer	CI
04-06	Axe Compute Names Kyle Okamoto President, Effective April 1, 2026	CI
04-02	Axe Compute appoints Kyle Okamoto as president effective April 1, 2026 - SEC filing	RE
04-01	Axe Compute Inc., 2025 Earnings Call, Apr 01, 2026

15/11/24	HC Wainwright Downgrades Predictive Oncology to Neutral From Buy	MT
30/06/21	PREDICTIVE ONCOLOGY : HC Wainwright Starts Predictive Oncology at Buy With $5 Price Target	MT

06-16	Axe Compute Secures $25.9 Million in Contracts for Long-Term Deployments of Blackwell and Grace Blackwell Compute	AQ
05-27	Axe Compute Receives $43M Payment for Landmark Contract	AQ
05-16	Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05-11	Axe Compute to Host Q1 2026 Financial Results Conference Call	AQ
05-04	Axe Compute Inc. (NASDAQ: AGPU) CEO Chris Miglino to Appear on Schwab Network May 4 and Cheddar May 6	AQ

16/03/21	MÄRKTE USA/Wall Street mit Fed-Sitzung in Lauerstellung
16/03/21	New Fortress Energy : MÄRKTE USA/Wall Street mit Fed-Sitzung uneinheitlich
16/03/21	New Fortress Energy : MÄRKTE USA/S&P-500 mit Rekordhoch trotz enttäuschender US-Daten
16/03/21	New Fortress Energy : MÄRKTE USA/Wenig verändert - US-Daten liefern gemischtes Bild
16/03/21	New Fortress Energy : MARKT USA/Wenig verändert - US-Daten könnten Impulse liefern

Precision Therapeutics Inc Stock Nasdaq

Stocks

US74033P1003

Biotechnology & Medical Research

Valuation: Precision Therapeutics Inc

Latest news : Precision Therapeutics Inc

Last Transcript: Precision Therapeutics Inc

Analysts' recommendations: Precision Therapeutics Inc

Press Releases: Precision Therapeutics Inc

News in other languages: Precision Therapeutics Inc

Quotes and Performance

Managers and Directors: Precision Therapeutics Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Christopher Miglino CEO	Chief Executive Officer	57	09/02/2026
Jeremy Yaukey-Witter DFI	Director of Finance/CFO	-	16/04/2026
Kyle Okamoto PSD	President	-	01/04/2026

Director	Title	Age	Since
Daniel Handley BRD	Director/Board Member	66	19/02/2020
Charles L. Nuzum CHM	Chairman	78	09/02/2026
Gregory St. Clair BRD	Director/Board Member	60	09/07/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PRECISION THERAPEUTICS INC	-7.56%	-8.33%	-	-	40.99M
LONZA GROUP AG	-0.22%	-0.40%	-13.00%	-13.09%	43.51B
REVOLUTION MEDICINES, INC.	+0.76%	+9.42%	+303.09%	+514.37%	33.29B
BEONE MEDICINES AG	-0.47%	-0.35%	+3.38%	+37.12%	29.34B
IQVIA HOLDINGS INC.	-4.74%	-6.31%	+10.75%	-20.59%	29.9B
CELLTRION, INC.	+0.06%	+2.71%	+13.31%	+21.11%	25.42B
ASCENDIS PHARMA A/S	-0.02%	+10.18%	-	-	14.36B
MEDPACE HOLDINGS, INC.	-0.98%	-1.86%	+53.43%	+102.89%	13.18B
EUROFINS SCIENTIFIC SE	-0.29%	-3.76%	+2.12%	+1.69%	12.72B
IONIS PHARMACEUTICALS, INC.	+1.67%	+1.35%	+105.56%	+80.93%	12.08B
Average	-1.20%	+0.67%	+59.83%	+90.55%	23.76B
Weighted average by Cap.	-0.68%	+0.72%	+61.62%	+99.87%

	2024	2025
Net sales	1.62M 1.4M 1.29M 1.21M 2.28M 153M 2.3M 15.26M 5.94M 75.21M 6.09M 5.96M 260M	125K 108K 99.37K 93.53K 176K 11.82M 177K 1.18M 458K 5.8M 470K 460K 20.07M
Net income	-12.66M -10.93M -10.04M -9.45M -17.77M -1.2B -17.92M -119M -46.34M -587M -47.53M -46.52M -2.03B	-233M -201M -185M -174M -327M -22B -330M -2.19B -853M -10.8B -875M -856M -37.35B
Net Debt	1.4M 1.2M 1.11M 1.04M 1.96M 132M 1.98M 13.12M 5.11M 64.67M 5.24M 5.13M 224M	-9.12M -7.87M -7.24M -6.81M -12.8M -861M -12.91M -85.77M -33.39M -423M -34.25M -33.51M -1.46B